MAPT and Alzheimer disease: Although the level of TFEB, the master transcriptional activator of lysosomal proteins, is not reduced in AD brains, further increasing it by delivering viral TFEB constructs has been shown to reduce Aβ and phospho-tau levels in AD mice [83, 84].